Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A once-monthly investigational drug called tilrekimig is showing real promise for eczema treatment. The trispecific antibody simultaneously blocks three inflammatory cytokines — IL-4, IL-13, and TSLP — and in a phase 2 trial, up to 61% of patients achieved significant skin clearance compared to just 9% on placebo. Notably, it showed no increase in conjunctivitis rates compared to placebo, a common concern with existing biologics.
A new investigational drug, tilrekimig, is emerging as a potential game-changer for moderate-to-severe atopic dermatitis (eczema). Unlike existing biologics that target a single cytokine, this trispecific antibody simultaneously blocks three key drivers of type 2 inflammation — IL-4, IL-13, and thymic stromal lymphopoietin (TSLP) — offering a broader therapeutic approach in a once-monthly injection.
In a two-stage phase 2 trial involving biologic-naïve adults, tilrekimig outperformed placebo across all dosing regimens. Response rates improved over time from week 8 to week 16, suggesting continued benefit with longer treatment — a promising signal heading into phase 3 planning.
By the Numbers:
Why it matters: Current biologics like dupilumab leave some patients with inadequate responses or side effects such as conjunctivitis. Tilrekimig's triple-targeting mechanism and comparable eye-safety profile to placebo could fill a meaningful gap in eczema care — if phase 3 confirms these early results.
